Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase Ib/II Study Of CRLX 101 (Cerulean) In Combination With Bevacizumab In The Treatment Of Patients With Advanced Renal Cell Carcinoma

Next Previous
X
Search
Trial Profile

Phase Ib/II Study Of CRLX 101 (Cerulean) In Combination With Bevacizumab In The Treatment Of Patients With Advanced Renal Cell Carcinoma

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 31 Mar 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Camptothecin (Primary) ; Bevacizumab
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 09 Jun 2016 According to a Cerulean Pharma media release, primary endpoint of recommended phase II dose (A primary aim in phase Ib is to determine the recommended phase II camptothecin dose has been met.
    • 04 Nov 2015 According to a Cerulean Pharma media release, results from this study were presented at the 2015 International Kidney Cancer Symposium.
    • 02 Jun 2015 Final results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top